Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Retevmo
Selpercatinib is a targeted therapy used to treat certain types of cancer, specifically those driven by alterations in the RET gene. It is a kinase inhibitor that selectively blocks the activity of the RET protein, hindering the growth and spread of cancer cells. This drug is classified as a small molecule inhibitor and is typically administered orally.
Selpercatinib is used to treat RET-fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid cancer, and other RET-altered cancers.
Outcome:
Increased risk of Torsades de Pointes
Mechanism:
Additive QT prolongation
Outcome:
Moderate increase in selpercatinib exposure
Mechanism:
Partial reduction in metabolism
Outcome:
Reduced selpercatinib absorption
Mechanism:
Chelation/altered pH
Most likely new formulation: Extended-release formulation (Year: 2026, 70% confidence)
Based on clinical trial data and post-market surveillance, there is a high likelihood (>80%) of selpercatinib maintaining its current approval status for RET-driven cancers.
Kinase Inhibitor, Antineoplastic Agent
Pyrrolopyrimidine